BRCA1		
Drug	Toxicity(LD50,mol/kg)	Ref
Resveratrol	1.6791	Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.
Alsterpaullone	2.4368	Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.
Irinotecan	2.796	Liposomal Irinotecan Achieves Significant Survival and Tumor Burden Control in a Triple Negative Breast Cancer Model of Spontaneous Metastasis.
Vinblastine	2.9111	Vinorelbine Plus Platinum in Patients with Metastatic Triple Negative Breast Cancer and Prior Anthracycline and Taxane Treatment.
Indometacin	4.0722	Anti-Inflammatory Agent Indomethacin Reduces Invasion and Alters Metabolism in a Human Breast Cancer Cell Line
AKT1		
Drug	Toxicity(LD50,mol/kg)	Ref
Danazol	1.3291	Danazol has potential to cause PKC translocation, cell cycle dysregulation, and apoptosis in breast cancer cells
Norethisterone	1.8788	Norethisterone acetate in the treatment of advanced breast cancer.
Dacarbazine	1.9602	Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway
Probucol	1.9829	Nanoassembly of probucol enables novel therapeutic efficacy in the suppression of lung metastasis of breast cancer.
Dipyridamole	2.1167	Dipyridamole prevents triple-negative breast-cancer progression.
ETS1		
Drug	Toxicity(LD50,mol/kg)	Ref
Resveratrol	1.6791	Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer
Prednisolone	1.8914	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Carbamazepine	2.2899	Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells
Mercaptopurine	2.3684	A phase II clinical trial of 6-mercaptopurine (6MP) and methotrexate in patients with BRCA defective tumours: a study protocol
Diclofenac	3.6447	Repurposing Drugs in Oncology (ReDO)â€”diclofenac as an anti-cancer agent
FOXC1		
Drug	Toxicity(LD50,mol/kg)	Ref
Sulfasalazine	1.4383	Anti-Cancer Effects of Sulfasalazine and Vitamin E Succinate in MDA-MB 231 Triple-Negative Breast Cancer Cells
Resveratrol	1.6791	Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer
Prednisolone	1.8914	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Carbamazepine	2.1131	Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells
Verapamil	3.4137	Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells
STAT3		
Drug	Toxicity(LD50,mol/kg)	Ref
Resveratrol	1.6791	Curcumin and Resveratrol as Promising Natural Remedies with Nanomedicine Approach for the Effective Treatment of Triple Negative Breast Cancer
Prednisolone	1.8914	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Carbamazepine	2.1131	Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells
Novobiocin	2.2899	Novobiocin Analogs as Potential Anticancer Agents.
Felodipine	2.4526	
MMP2		
Drug	Toxicity(LD50,mol/kg)	Ref
Prednisolone	1.8914	A phase II trial of abiraterone acetate plus prednisone in patients with triple-negative androgen receptor positive locally advanced or metastatic breast cancer (UCBG 12-1).
Carbamazepine	2.1131	Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells
tamoxifen	1.9882	The role of tamoxifen in the treatment and prevention of breast cancer.
Dexamethasone	2.1482	Dexamethasone co-medication in cancer patients undergoing chemotherapy causes substantial immunomodulatory effects with implications for chemo-immunotherapy strategies
lomustine	3.5549	Oral second- and third-line lomustine-etoposide-cyclophosphamide chemotherapy for small cell lung cancer.
NFE2L1		
Drug	Toxicity(LD50,mol/kg)	Ref
Verapamil	3.4137	Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells
Resveratrol	1.6791	Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.
Probucol	1.9829	Nanoassembly of probucol enables novel therapeutic efficacy in the suppression of lung metastasis of breast cancer.
sulindac	3.0989	Effects of sulindac sulfide on proliferation and apoptosis of human breast cancer cell
Carbamazepine	2.1131	Inhibitory effect of carbamazepine on proliferation of estrogen-dependent breast cancer cells
